Los Angeles Capital Management
KROS icon

Los Angeles Capital Management’s Keros Therapeutics KROS Stock Holding History

Los Angeles Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$903K Sell
84,372
-87,824
-51% -$978K ﹤0.01% 766
2026
Q1 		$1.9M Buy
172,196
+138,425
+410% +$2.14M 0.01% 514
2025
Q4 		$508K Sell
33,771
-3,232
-9% -$56.7K ﹤0.01% 881
2025
Q3 		$585K Sell
37,003
-4,706
-11% -$69.5K ﹤0.01% 880
2025
Q2 		$557K Buy
+41,709
New +$563K ﹤0.01% 827

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Los Angeles Capital Management's KROS Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Keros Therapeutics (KROS) stake by 51% in Q2 2026, selling an estimated $978K and leaving 84,372 shares worth $903K. The position accounts for ﹤0.01% of the portfolio, ranked #766.

Los Angeles Capital Management first reported a position in KROS in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.9M in Q1 2026. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Los Angeles Capital Management held 84,372 shares of Keros Therapeutics worth $903K as of Q2 2026.
  • Los Angeles Capital Management sold 87,824 Keros Therapeutics shares in Q2 2026, an estimated $978K.
  • Keros Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #766 holding.
  • Los Angeles Capital Management first reported a position in Keros Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Los Angeles Capital Management's Keros Therapeutics position peaked at $1.9M in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.